R

    Regencell Bioscience Holdings Ltd (RGC)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $5.51
    +0.01 (+0.18%)

    Market Cap: $2.72B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    PeriodReportedEst.SurpriseB/MYoY
    Mar 26
    Reported Jun 15
    		$N/AN/AN/ABeat-
    Sep 25
    Reported Oct 24
    		$0.00$0.00N/ABeat+100.0%
    Jun 25
    Reported Jul 16
    		$N/AN/AN/ABeat-
    Mar 25
    Reported Jun 26
    		$0.00$0.00N/ABeat+100.0%
    Sep 24
    Reported Oct 25
    		$0.00$0.00N/ABeat+100.0%
    Sep 22
    Reported Oct 31
    		$-0.30$0.00N/AMiss-492.9%
    Mar 22
    Reported Jun 2
    		$-0.29$0.00N/AMiss-1636.5%
    Sep 21
    Reported Oct 29
    		$-0.11$0.00N/AMiss-558.7%
    Mar 21
    Reported Apr 26
    		$-33.38$0.00N/AMiss-129783.3%
    Dec 20
    Reported Mar 31
    		$-0.05$0.00N/AMiss-96.9%
    Sep 20
    Reported Dec 31
    		$-0.02$0.00N/AMiss-12.1%
    Jun 20
    Reported Sep 30
    		$-0.02$0.00N/AMiss-12.1%
    Mar 20
    Reported Jun 30
    		$-0.03$0.00N/AMiss-
    Dec 19
    Reported Mar 31
    		$-0.03$0.00N/AMiss-
    Sep 19
    Reported Dec 31
    		$-0.01$0.00N/AMiss-
    Jun 19
    Reported Sep 30
    		$-0.01$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-6.14EV/EBITDA-44.58x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-177.70%ROIC-1142.18%
    Financial Health
    Debt/Equity0.21xInterest CoverageN/A
    Current Ratio1.42xQuick Ratio1.42x
    Trading Statistics
    Beta1.49Avg Volume162.75K
    52-Week High$69.0052-Week Low$4.51

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.49
    SMA 20$5.45
    SMA 50$5.99
    SMA 200$20.05
    EMA 10$5.48
    EMA 20$5.61
    EMA 50$8.12
    EMA 200$15.78

    MACD

    Line: -0.41Signal: -0.59Hist: 0.18

    ADX

    ADX: 15.1+DI: 18.9-DI: 17.8

    Aroon & PSAR

    Aroon Up20.0
    Aroon Down44.0
    PSAR$6.30

    Bollinger Bands

    Upper Band$5.95
    Lower Band$4.96
    %B Position1810%(Upper)
    Band Width0.56

    RSI (14-Day)

    Neutral
    41.9

    Momentum Oscillators

    Stoch %K47.3
    Stoch %D48.6
    Williams %R-56.1
    ROC (10d)3.0%
    Momentum0.16
    CCI (20d)5.6
    MFI (14d)62.8

    Volatility Measures

    ATR (14d)$0.50(9.1%)
    StdDev (20d)0.25
    Hist Vol55.7%(High)

    Volume Flow

    VWAP$5.49
    OBV39.1M
    AD Line-158.5M
    CMF (20d)-0.207

    Volume Metrics

    Avg Vol (20d)156.2K
    Vol Ratio0.3x(Low)
    VWMA (20d)$5.47

    Pivot Points

    R3$5.91
    R2$5.81
    R1$5.65
    Pivot Point$5.55
    S1$5.39
    S2$5.29
    S3$5.13

    Advanced Oscillators

    TSI-20.92
    Ultimate Osc53.1
    KST-52.35

    Financial Data

    QuarterMar 2026Sep 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022
    Total RevenueN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A$-2,341,800,000
    Cost of Revenue$40,839N/AN/AN/AN/AN/AN/A$769,687$769,687N/AN/A$604,397
    Gross Profit$-40,839N/AN/AN/AN/AN/AN/A$-769,687$-769,687N/AN/A$-2,342,404,397
    Operating Expenses$5.30M$1.79M$1.98M$988,918$1,212$1,212N/AN/AN/AN/AN/AN/A
    R&D$416,030$440,908$507,381$253,691$0$0$0$0$0$0$0$0
    SG&A$0$1.35M$1.47M$731,563$0$0$0$0$0$0$0$0
    Operating Income$-5,340,462$-1,792,150$-1,977,835$-988,918$-1,212$-1,212N/AN/AN/AN/AN/AN/A
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-5,317,987$-1,730,600$-1,853,613$-926,807$-1,088$-1,088$0$0$0$0$0$0
    Income Tax Expense$0$0$0$57,887$0$0$0$0$0$0$0$0
    Net Income$-5,317,987$-1,730,600$-1,853,613$-926,807$-1,117$-1,117N/AN/AN/AN/AN/AN/A
    EBITDA$-5,299,623$-1,730,600$-1,777,170$-912,473$-1,139$-1,139N/A$-1,082,644$-3,360,524$-1,384,539N/A$-1,677,223
    EBIT$-5,340,462$-1,655,402$-1,853,615$-988,918N/AN/A$-1,155,928N/AN/AN/A$-5,029,999N/A
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RGC

    News

    Regencell Bioscience (RGC) Short Interest & Short Float | Updated Aug 2026 $RGC

    Regencell Bioscience (RGC) had a short interest of 903,042 shares as of July 31, 2026, which is a 2.91% decrease from the previous report. This represents 0.18% of its public float, with a short interest ratio of 4.1 days to cover. The article provides historical short interest data and explains common short selling metrics for investors.

    MarketBeat•8/11/26•
    Neutral

    RGC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce

    Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Regencell Bioscience Holdings Ltd. (NASDAQ:RGC) and its officers. The lawsuit, filed on behalf of investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, alleges the company made materially false and misleading statements regarding its business and operations, exposing investors to significant financial risk and regulatory scrutiny due to market manipulation. Investors with substantial losses have until June 23, 2026, to request to be appointed as lead plaintiff.

    The National Law Review•8/9/26•
    Bearish

    Regencell Bioscience Holdings Ltd (RGC) Earnings Forecast: Future EPS & Revenue Growth Estimates

    This article provides an earnings forecast for Regencell Bioscience Holdings Ltd (RGC), detailing future EPS and revenue growth estimates. It highlights the stock's current performance, market capitalization, and includes a peer comparison in the biotechnology and medical research sector. The forecast data was updated on August 8, 2026.

    TradingKey•8/6/26•
    Somewhat-Bullish

    RGC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regencell Bioscience Holdings Ltd. Shareholders Have Opportunity to Lead Class Action Lawsuit!

    Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Regencell Bioscience Holdings Ltd. (NASDAQ:RGC) and its officers. The lawsuit alleges that Regencell made materially false and misleading statements regarding its business, operations, and compliance policies between October 28, 2024, and October 31, 2025. Investors who purchased Regencell securities during this period have until June 23, 2026, to request to be appointed lead plaintiff in the case.

    The National Law Review•8/4/26•
    Bearish

    Regencell Bioscience Holdings Ltd (RGC) Earnings Forecast: Future EPS & Revenue Growth Estimates

    This article provides an earnings forecast for Regencell Bioscience Holdings Ltd (RGC), detailing future EPS and revenue growth estimates. It includes a snapshot of RGC's current stock performance, market capitalization, and various analytical dimensions such as valuation, earnings forecast, and risk assessment. The forecast data was updated on August 2, 2026.

    TradingKey•8/1/26•
    Somewhat-Bullish

    Frequently Asked Questions About RGC

    Does RGC pay dividends?
    Regencell Bioscience Holdings Ltd (RGC) does not currently pay a regular dividend.
    What is RGC's market cap?
    Regencell Bioscience Holdings Ltd (RGC) has a market capitalization of $2.72B with a current stock price of $5.51.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In